CSE : ENBI | OTCQB : ENTBF
Leveraging emerging biotechnology, Entheon Biomedical Corp. is pioneering a leading-edge addiction recovery solution that harnesses the therapeutic potential of patient-centric psychedelic medicine to remedy the underlying causes of substance use disorder. Focusing primarily on the powerful DMT molecule, Entheon exists to invert the addiction recovery ratio, turning the ‘untreatable case’ and ‘lost cause’ from the norm to the exception.
Developing a comprehensive psychedelic medicine platform that incorporates technology and the ideal psychedelic molecule for the treatment of addiction
Entheon IQ is a fully integrated psychedelic medicine platform that utilizes genetics and EEG biomarkers to personalize assessment, monitoring, and therapy design, replacing uncertainty and subjectivity with data and empiricism
Conducting clinical trials with DMT which is a highly potent and short-acting psychedelic molecule. This flexibility allows for greater control, safety and personalization of program design
Copyright © 2021. All rights reserved.